BR112015022762A2 - composto éster de ácido guanidino benzóico - Google Patents
composto éster de ácido guanidino benzóicoInfo
- Publication number
- BR112015022762A2 BR112015022762A2 BR112015022762A BR112015022762A BR112015022762A2 BR 112015022762 A2 BR112015022762 A2 BR 112015022762A2 BR 112015022762 A BR112015022762 A BR 112015022762A BR 112015022762 A BR112015022762 A BR 112015022762A BR 112015022762 A2 BR112015022762 A2 BR 112015022762A2
- Authority
- BR
- Brazil
- Prior art keywords
- acid ester
- benzoic acid
- ester compound
- agent
- prevention
- Prior art date
Links
- -1 guanidino benzoic acid ester compound Chemical class 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 102000004142 Trypsin Human genes 0.000 abstract 3
- 108090000631 Trypsin Proteins 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 3
- 239000012588 trypsin Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 208000017169 kidney disease Diseases 0.000 abstract 2
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 abstract 1
- 206010033649 Pancreatitis chronic Diseases 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
- 208000007386 hepatic encephalopathy Diseases 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 235000020905 low-protein-diet Nutrition 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D333/40—Thiophene-2-carboxylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
resumo composto éster de ácido guanidino benzóico [problema] fornecer um composto que seja útil como um agente para a pre-venção e / ou tratamento de doenças renais. [meios para solução] os presentes inventores estudaram compostos com uma atividade inibidora de tripsina, e confirmaram que um composto de éster de ácido guanidino benzóico tem uma atividade inibidora de tripsina, completando as-sim a presente invenção. o composto de éster de ácido guanidino benzóico da pre-sente invenção pode ser utilizado como um agente para a prevenção e / ou trata-mento de doenças renais (por exemplo, doença renal crônica, nefrite aguda, insufi-ciência renal aguda, e semelhantes) como um agente que irá substituir a terapêuti-ca com dieta de baixa proteína, e / ou como um agente para a prevenção e / ou tra-tamento de doenças relacionadas com a tripsina (por exemplo, pancreatite crônica, doença do refluxo gastroesofágico, encefalopatia hepática, gripe, e semelhantes).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013-050011 | 2013-03-13 | ||
JP2013050011 | 2013-03-13 | ||
PCT/JP2014/056601 WO2014142219A1 (ja) | 2013-03-13 | 2014-03-13 | グアニジノ安息香酸エステル化合物 |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112015022762A2 true BR112015022762A2 (pt) | 2017-07-18 |
BR112015022762A8 BR112015022762A8 (pt) | 2018-01-23 |
BR112015022762B1 BR112015022762B1 (pt) | 2022-08-16 |
Family
ID=51536870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015022762-7A BR112015022762B1 (pt) | 2013-03-13 | 2014-03-13 | Composto de éster do ácido guanidinobenzóico, composição farmacêutica, e, uso do composto |
Country Status (30)
Country | Link |
---|---|
US (1) | US9969709B2 (pt) |
EP (1) | EP2975023B1 (pt) |
JP (1) | JP6314129B2 (pt) |
KR (1) | KR102145649B1 (pt) |
CN (1) | CN105051008B (pt) |
AU (1) | AU2014230583B2 (pt) |
BR (1) | BR112015022762B1 (pt) |
CA (1) | CA2905606C (pt) |
CY (1) | CY1120552T1 (pt) |
DK (1) | DK2975023T3 (pt) |
ES (1) | ES2684045T3 (pt) |
HK (1) | HK1216246A1 (pt) |
HR (1) | HRP20181371T1 (pt) |
HU (1) | HUE039526T2 (pt) |
IL (1) | IL241541B (pt) |
LT (1) | LT2975023T (pt) |
MX (1) | MX2015012604A (pt) |
MY (1) | MY194604A (pt) |
PH (1) | PH12015502023B1 (pt) |
PL (1) | PL2975023T3 (pt) |
PT (1) | PT2975023T (pt) |
RS (1) | RS57568B1 (pt) |
RU (1) | RU2661895C2 (pt) |
SG (2) | SG11201507411TA (pt) |
SI (1) | SI2975023T1 (pt) |
TR (1) | TR201809418T4 (pt) |
TW (1) | TWI666196B (pt) |
UA (1) | UA118668C2 (pt) |
WO (1) | WO2014142219A1 (pt) |
ZA (1) | ZA201506745B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2975023T3 (en) | 2013-03-13 | 2018-08-20 | Takeda Pharmaceuticals Co | Guanidine benzoic acid ester compound |
US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US9346776B2 (en) * | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
JP2018080109A (ja) * | 2015-03-16 | 2018-05-24 | 武田薬品工業株式会社 | 治療剤 |
EP3275874B1 (en) * | 2015-03-27 | 2019-10-30 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
CN105218289B (zh) * | 2015-10-15 | 2017-08-01 | 浙江大学 | 一种不饱和脂肪酸原位加氢脱羧制备长链烷烃的方法 |
US11465965B2 (en) | 2017-11-02 | 2022-10-11 | Ube Industries, Ltd. | Double-headed protease inhibitor |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5289640A (en) | 1976-01-21 | 1977-07-27 | Ono Pharmaceut Co Ltd | Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives |
JPS5753454A (en) | 1980-09-16 | 1982-03-30 | Torii Yakuhin Kk | Guanidinobenzoate and anticomplementary agent |
AU527371B2 (en) | 1980-09-16 | 1983-03-03 | Torii & Co., Ltd. | Amidine |
JP2886586B2 (ja) | 1989-12-28 | 1999-04-26 | 雪印乳業株式会社 | 新規グアニジノ安息香酸誘導体及びその酸付加塩 |
US5116985A (en) | 1989-12-28 | 1992-05-26 | Snow Brand Milk Products Co., Ltd. | Isoquinoline derivatives and salts thereof |
JPH0446148A (ja) | 1990-06-08 | 1992-02-17 | Asahi Chem Ind Co Ltd | 4―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤 |
JPH06192085A (ja) * | 1992-08-31 | 1994-07-12 | Yuji Inada | ダニアレルギー治療剤 |
EP0673924A4 (en) | 1992-12-10 | 1996-04-24 | Teikoku Chem Ind Co Ltd | PROPRIONIC ACID DERIVATIVE. |
JPH0753500A (ja) | 1993-08-16 | 1995-02-28 | Sanwa Kagaku Kenkyusho Co Ltd | グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤 |
JPH0848664A (ja) | 1994-08-05 | 1996-02-20 | Hisamitsu Pharmaceut Co Inc | 新規なグアニジノ安息香酸エステル誘導体 |
JPH09124571A (ja) * | 1995-11-01 | 1997-05-13 | Japan Tobacco Inc | アミド化合物及びその用途 |
EP0893437A4 (en) * | 1996-04-10 | 2000-12-27 | Ono Pharmaceutical Co | GUANIDINO TRYPTASE INHIBITOR |
JPH10101556A (ja) | 1996-09-27 | 1998-04-21 | Ono Pharmaceut Co Ltd | ファクターd阻害剤 |
JPH10251239A (ja) | 1997-03-14 | 1998-09-22 | Mochida Pharmaceut Co Ltd | 新規4h−3,1−ベンゾオキサジン−4−オン誘導体 |
JPH10306025A (ja) | 1997-05-07 | 1998-11-17 | Touin Yokohama Univ | 花粉プロテアーゼ阻害剤 |
US7671057B2 (en) | 2004-11-08 | 2010-03-02 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for type II diabetes comprising protease-inhibiting compound |
CA2588087A1 (en) | 2004-11-15 | 2006-05-18 | Obe Therapy Biotechnology S.A.S. | Methods of reducing body fat |
DE602004015169D1 (de) | 2004-11-26 | 2008-08-28 | Nutricia Nv | Kleinkindernahrung mit proteasehemmer |
WO2006083781A1 (en) | 2005-01-31 | 2006-08-10 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
US20090062297A1 (en) | 2006-01-12 | 2009-03-05 | Heidebrecht Richard W | Hydroxyalkylarylamide Derivatives |
PL2225261T3 (pl) | 2007-12-03 | 2016-09-30 | Inhibitory boropeptydowe enteropeptydaz i ich zastosowania w leczeniu otyłości, nadwagi i/lub chorób związanych z nieprawidłowym metabolizmem tłuszczów | |
WO2011071048A1 (ja) | 2009-12-07 | 2011-06-16 | 味の素株式会社 | ヘテロアリールカルボン酸エステル誘導体 |
WO2012169579A1 (ja) | 2011-06-07 | 2012-12-13 | 味の素株式会社 | ヘテロ環カルボン酸エステル誘導体 |
KR101981347B1 (ko) | 2011-09-15 | 2019-05-22 | 아스텔라스세이야쿠 가부시키가이샤 | 구아니디노벤조산 화합물 |
WO2013102899A1 (en) | 2012-01-03 | 2013-07-11 | Oramed Ltd. | Methods and compositions for treating diabetes |
US9024044B2 (en) | 2012-06-14 | 2015-05-05 | Ajinomoto Co., Inc. | Heteroarylcarboxylic acid ester derivative |
JP2016505613A (ja) | 2013-01-03 | 2016-02-25 | オラムド エルティーディー. | Nafld、脂肪肝、および、その後遺症を処置するための方法および組成物 |
CA2903215C (en) | 2013-03-08 | 2021-07-20 | Amgen Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
DK2975023T3 (en) | 2013-03-13 | 2018-08-20 | Takeda Pharmaceuticals Co | Guanidine benzoic acid ester compound |
US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
-
2014
- 2014-03-13 DK DK14763790.4T patent/DK2975023T3/en active
- 2014-03-13 ES ES14763790.4T patent/ES2684045T3/es active Active
- 2014-03-13 RS RS20180861A patent/RS57568B1/sr unknown
- 2014-03-13 KR KR1020157027906A patent/KR102145649B1/ko active IP Right Grant
- 2014-03-13 TR TR2018/09418T patent/TR201809418T4/tr unknown
- 2014-03-13 AU AU2014230583A patent/AU2014230583B2/en active Active
- 2014-03-13 RU RU2015143562A patent/RU2661895C2/ru active
- 2014-03-13 TW TW103109057A patent/TWI666196B/zh active
- 2014-03-13 SG SG11201507411TA patent/SG11201507411TA/en unknown
- 2014-03-13 PL PL14763790T patent/PL2975023T3/pl unknown
- 2014-03-13 SI SI201430865T patent/SI2975023T1/sl unknown
- 2014-03-13 PT PT147637904T patent/PT2975023T/pt unknown
- 2014-03-13 CN CN201480014813.4A patent/CN105051008B/zh active Active
- 2014-03-13 UA UAA201509922A patent/UA118668C2/uk unknown
- 2014-03-13 WO PCT/JP2014/056601 patent/WO2014142219A1/ja active Application Filing
- 2014-03-13 BR BR112015022762-7A patent/BR112015022762B1/pt active IP Right Grant
- 2014-03-13 MX MX2015012604A patent/MX2015012604A/es active IP Right Grant
- 2014-03-13 EP EP14763790.4A patent/EP2975023B1/en active Active
- 2014-03-13 HU HUE14763790A patent/HUE039526T2/hu unknown
- 2014-03-13 US US14/775,274 patent/US9969709B2/en active Active
- 2014-03-13 LT LTEP14763790.4T patent/LT2975023T/lt unknown
- 2014-03-13 JP JP2015505541A patent/JP6314129B2/ja active Active
- 2014-03-13 CA CA2905606A patent/CA2905606C/en active Active
- 2014-03-13 SG SG10201707504VA patent/SG10201707504VA/en unknown
- 2014-03-13 MY MYPI2015703099A patent/MY194604A/en unknown
-
2015
- 2015-09-09 PH PH12015502023A patent/PH12015502023B1/en unknown
- 2015-09-10 IL IL241541A patent/IL241541B/en active IP Right Grant
- 2015-09-11 ZA ZA2015/06745A patent/ZA201506745B/en unknown
-
2016
- 2016-04-13 HK HK16104215.3A patent/HK1216246A1/zh unknown
-
2018
- 2018-08-09 CY CY20181100832T patent/CY1120552T1/el unknown
- 2018-08-27 HR HRP20181371TT patent/HRP20181371T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015022762A2 (pt) | composto éster de ácido guanidino benzóico | |
EA201490632A1 (ru) | Соединение гуанидинобензойной кислоты | |
BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
CL2018002532A1 (es) | Composición farmacéutica que comprende empagliflozina y sus usos | |
BR112015001419A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
BR112014017466A8 (pt) | composto de pirazinacarboxamida | |
BR112017007144A2 (pt) | ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição. | |
BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
BR112012002134B8 (pt) | compostos inibidores de apaf-1 | |
BR112017007072A2 (pt) | compostos de triazolopiridina e métodos para o tratamento de fibrose cística | |
BR112014018879A8 (pt) | Composto e composição farmacêutica e combinação compreendendo dito composto | |
BR112017003745A2 (pt) | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico | |
BR112014009415A2 (pt) | inibidores de arginase e suas aplicações terapêuticas | |
BR112016022593A2 (pt) | composições e métodos para modular a expressão do fator b do complemento | |
BR112012025390B8 (pt) | Composto de tetraidrobenzotiofeno ou sal do mesmo e seu uso no tratamento ou prevenção de hiperfosfatemia, bem como composição farmacêutica compreendendo o dito composto | |
BR112019007576A2 (pt) | compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais | |
BR112015022092A2 (pt) | derivado de di-hidropiridazina-3,5-diona | |
BR112015022650A2 (pt) | inibidores de cinase induzível por sal macrocíclico | |
BR112016029067A2 (pt) | ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios? | |
BR112015019412A2 (pt) | inibidores de bace1 | |
UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
BR112016013754A2 (pt) | Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma | |
BR112016029065A2 (pt) | ?composto, composição farmacêutica, e, uso de um composto? | |
BR112016026470A8 (pt) | composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto | |
BR112017020053A2 (pt) | novo composto heterocíclico, método para a preparação do mesmo e composição farmacêutica compreendendo o mesmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/03/2014, OBSERVADAS AS CONDICOES LEGAIS |